ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SRRK vs CGON // OPERATING MARGIN

Scholar Rock Holding Corporation (NASDAQ) VS. CG Oncology Inc. (NASDAQ) • 15-METRIC TALLY: SRRK 1 — CGON 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRRK VS. CGON) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SRRK CGON SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -20.80% -14.20 CGON /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.59% -2.35% -3.24 CGON /fcf-yield <GO>
Operating Margin ACTIVE — -12.10% — TIE /operating-margins <GO>
Net Profit Margin — -10.20% — TIE /net-margins <GO>
Revenue Growth (YoY) 7.70% 8.80% -1.10 CGON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 13.67 26.00 -12.33 CGON /balance-sheet <GO>
Piotroski F-Score Quality 5/9 5/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.5 41.5 +3.00 SRRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.02 1.07 -0.05 CGON /macro-sensitivity <GO>
Forward P/E Multiple 32.0x 20.0x +12.00 CGON /forward-pe <GO>
Enterprise Scale & Market Cap $5.23B $5.49B -$266.4M CGON /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SRRK REV CGON REV SRRK GROSS % CGON GROSS % SRRK FCF CGON FCF
FY 2025 $1.08B $534.2M — — -$300.6M -$132.5M
FY 2024 $705.8M $321.1M — — -$201.0M -$78.9M
FY 2023 $479.6M $155.3M — — -$145.2M -$45.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRRK // BETA 1.02
CGON // BETA 1.07